The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | NUTRIVENTION-5: a decentralized trial of a plant-based diet during induction therapy in NDMM
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the ongoing randomized, decentralized NUTRIVENTION-5 study (NCT07226609), evaluating whether a high-fiber, plant-based diet can improve treatment response to induction therapy and quality of life in patients with newly diagnosed multiple myeloma (NDMM). The study is actively enrolling patients across the United States who are receiving quadruplet induction with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
